Indivior to pay $385 million to end Suboxone monopoly lawsuits

This post was originally published on this site

Indivior had in June agreed to pay $102.5 million to settle a lawsuit by dozens of U.S. states regarding the claims.

The agreement with the direct purchasers will mark the end of the multi-district litigation relating to Suboxone, it said.

Indivior said it will take a charge of $228 million in the third quarter, above the current remaining provision of $157 million, which will be excluded from adjusted earnings.